» Authors » Claudia Lobato da Silva

Claudia Lobato da Silva

Explore the profile of Claudia Lobato da Silva including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 43
Citations 934
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Carmelo J, Fernandes-Platzgummer A, Diogo M, Lobato da Silva C, Cabral J
Biotechnol J . 2015 Jul; 10(8):1235-47. PMID: 26136376
Human mesenchymal stem/stromal cells (MSC) are promising candidates for cell-based therapies and the development of microcarrier-based cultures in scalable bioreactors with well-defined xenogeneic-free components represent important milestones towards the clinical-scale...
12.
Oliveira N, Sirgado T, Reis L, Pinto L, Lobato da Silva C, Ferreira F, et al.
J Mech Behav Biomed Mater . 2014 Oct; 40:413-425. PMID: 25305635
Chitosan biocompatibility and biodegradability properties make this biopolymer promising for the development of advanced internal fixation devices for orthopedic applications. This work presents a detailed study on the production and...
13.
Boura J, Vance M, Yin W, Madeira C, Lobato da Silva C, Porada C, et al.
Mol Ther Methods Clin Dev . 2014 Oct; 2014(1). PMID: 25279386
Mesenchymal stromal cells (MSC) constitutively express low levels of human leukocyte antigen-G (HLA-G), which has been shown to contribute to their immunomodulatory and anti-inflammatory properties. Here, we hypothesized that overexpression...
14.
Oliveira P, Lobato da Silva C, Cabral J
Stem Cells . 2014 Aug; 32(11):2824-32. PMID: 25078438
Genomic instability is recognized as one of the most important hurdles in the expanding field of stem cell-based therapies. In the recent years, an accumulating body of evidence has shown...
15.
Carmelo J, Fernandes-Platzgummer A, Cabral J, Lobato da Silva C
Methods Mol Biol . 2014 Jul; 1283:147-59. PMID: 25063496
The clinical demand for human mesenchymal stem/stromal cells (MSC) drives the need for reproducible, cost-effective, and good manufacturing practices (GMP)-compliant ex vivo expansion protocols. Bioprocess engineering strategies, namely controlled stirred...
16.
Canadas R, Cavalheiro J, Guerreiro J, de Almeida M, Pollet E, Lobato da Silva C, et al.
Int J Biol Macromol . 2014 May; 71:131-40. PMID: 24836511
This integrated study shows that waste glycerol can be bio-valorized by the fabrication of electrospun scaffolds for stem cells. Human mesenchymal stem cells (hMSC) provide an interesting model of regenerating...
17.
Ribeiro A, Laranjeira P, Mendes S, Velada I, Leite C, Andrade P, et al.
Stem Cell Res Ther . 2014 Jan; 4(5):125. PMID: 24406104
Introduction: The ability to self-renew, be easily expanded in vitro and differentiate into different mesenchymal tissues, render mesenchymal stem cells (MSCs) an attractive therapeutic method for degenerative diseases. The subsequent...
18.
Dos Santos F, Andrade P, Lobato da Silva C, Cabral J
Biotechnol J . 2013 Apr; 8(6):644-54. PMID: 23625834
The many clinical trials currently in progress will likely lead to the widespread use of stem cell-based therapies for an extensive variety of diseases, either in autologous or allogeneic settings....
19.
Oliveira P, Lobato da Silva C, Cabral J
PLoS One . 2013 Apr; 8(3):e59907. PMID: 23555828
Mitochondrial DNA (mtDNA) deletion mutations are frequently observed in aged postmitotic tissues and are the cause of a wide range of human disorders. Presently, the molecular bases underlying mtDNA deletion...
20.
Boura J, Dos Santos F, Gimble J, Cardoso C, Madeira C, Cabral J, et al.
Hum Gene Ther Methods . 2013 Jan; 24(1):38-48. PMID: 23360350
Nonviral gene delivery to human mesenchymal stem/stromal cells (MSC) can be considered a very promising strategy to improve their intrinsic features, amplifying the therapeutic potential of these cells for clinical...